Martinez Marie-Carmen Muniz, Nortier Joëlle, Vereerstraeten Pierre, Vanherweghem Jean-Louis
Department of Nephrology, Hôpital Erasme, Brussels, Belgium.
Nephrol Dial Transplant. 2002 Mar;17(3):408-12. doi: 10.1093/ndt/17.3.408.
Renal failure after ingestion of Chinese herbs between 1990 and 1992 was related to the replacement of Stephania tetrandra by Aristolochia fangchi (ST-AF), containing nephrotoxic and carcinogenic aristolochic acids. However, the relationship between ST-AF and renal failure is still a matter of debate. We therefore tested the impact of the ST-AF ingested dose on the progression of renal function deterioration.
Analysis of medical charts and prescriptions between 1990 and 1992 was carried out to determine the presence of risk factors for kidney failure and the cumulative dose of pill components. Individual progression rate of renal impairment was studied by the time-course of the inverse of blood creatinine level (1/P(creat)).
Patients were divided into an end-stage renal disease (ESRD) group (n=44) and a chronic renal failure (CRF) group (n=27) according to their P(creat) at the time of this study. The mean number of risk factors (+/-SD) was equally distributed within both groups (1.50+/-0.18 vs 1.59+/-0.17, P=0.74). Patients from the ESRD group ingested significantly higher cumulative doses of ST--AF (192+/-13.1 g vs 138+/- 16.3 g), Magnolia officinalis, (80.1+/-6.3 g vs 59.8+/-11.7 g), diethylpropion (14.7+/-1.4 g vs 10.0+/-1.4 g) and fenfluramine (14.1+/-1.6 g vs 8.7+/-1.3 g). In the ESRD group, some patients who had received steroids had a slower progression to ESRD than the others. In multiple regression analysis, ST-AF emerged as the only significant drug predicting the slope of the progression of renal failure. Moreover, hypothesizing a linear dose-response relationship, the risk of developing ESRD linearly increased with ST-AF doses.
The relationship between the cumulative ST-AF dose and the renal failure progression rate confirms that regular ingestion of Aristolochia sp. extracts is causally involved in the onset of chronic interstitial nephropathy leading to ESRD.
1990年至1992年间,服用中草药后出现肾衰竭与广防己取代防己有关,广防己含有肾毒性和致癌性马兜铃酸。然而,广防己与肾衰竭之间的关系仍存在争议。因此,我们测试了广防己摄入剂量对肾功能恶化进展的影响。
对1990年至1992年间的病历和处方进行分析,以确定肾衰竭的危险因素和药丸成分的累积剂量。通过血肌酐水平倒数(1/P(creat))的时间进程研究个体肾功能损害的进展率。
根据本研究时的P(creat),将患者分为终末期肾病(ESRD)组(n = 44)和慢性肾衰竭(CRF)组(n = 27)。两组中危险因素的平均数量(±标准差)分布均匀(1.50±0.18对1.59±0.17,P = 0.74)。ESRD组患者摄入的广防己累积剂量(192±13.1克对138±16.3克)、厚朴(80.1±6.3克对59.8±11.7克)、二乙丙胺苯丙酮(14.7±1.4克对10.0±1.4克)和芬氟拉明(14.1±1.6克对8.7±1.3克)明显更高。在ESRD组中,一些接受过类固醇治疗的患者进展至ESRD的速度比其他患者慢。在多元回归分析中,广防己是唯一预测肾衰竭进展斜率的显著药物。此外,假设存在线性剂量反应关系,发生ESRD的风险随广防己剂量线性增加。
广防己累积剂量与肾衰竭进展率之间的关系证实,定期摄入马兜铃属提取物与导致ESRD的慢性间质性肾病的发生有因果关系。